Dergiler / Clinical and Experimental Health Sciences / 2022 / Cilt: 12 - Sayı: 3

Development and Validation of a Rapid HPLC-DAD Method for Determination of Favipiravir in Pharmaceutical Formulation

Sayfa
648–652
Yayın Tarihi
2022-09-28
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: As a result, it was concluded that the developed method can be used successfully in the determination of favipiravir in pharmaceutical preparations.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim of this work was to develop and validate a rapid and simple high-performance liquid chromatography method with a diode- array detector (HPLC-DAD) for determination of favipiravir in bulk and tablet formulations.
📊
Temel Bulgular & Veri:Methods: The chromatographic analysis was performed at 30 °C with a Poroshell 120EC-C18 column (4.6 x 50 mm, 2.7 µm).
💡
Sonuç & Katkı:Conclusion: As a result, it was concluded that the developed method can be used successfully in the determination of favipiravir in pharmaceutical preparations.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:COVID-19 treatment · HPLC · validation

Abstract

Objective: The aim of this work was to develop and validate a rapid and simple high-performance liquid chromatography method with a diode- array detector (HPLC-DAD) for determination of favipiravir in bulk and tablet formulations. Methods: The chromatographic analysis was performed at 30 °C with a Poroshell 120EC-C18 column (4.6 x 50 mm, 2.7 µm). The mobile phase was a mixture of 0.1% formic acid in water and 0.1% formic acid in acetonitrile (90:10, v/v). The run time was 5 min at a flow rate of 0.5 mL/min. Results: The proposed method was successfully validated in terms of precision, accuracy, linearity, robustness, limits of detection (LOD) and quantification (LOQ) parameters. The calibration plot was linear over a concentration range of 10-100 µg/mL. The LOD and LOQ values were found to be 0.58 µg/mL and 2.03 µg/mL, respectively. The average recovery values were found to vary from 99.45 percent to 104.29 percent. Conclusion: As a result, it was concluded that the developed method can be used successfully in the determination of favipiravir in pharmaceutical preparations.

🔖

Bu Makaleye Atıf Yap

TAŞKIN, D. (2022). Development and Validation of a Rapid HPLC-DAD Method for Determination of Favipiravir in Pharmaceutical Formulation. Clinical and Experimental Health Sciences, Cilt: 12 - Sayı: 3, 648–652. https://ajindex.com/articles/481075

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Ibraam EM, Heba E, Fathalla B, Adel EI. Green micellar solvent- free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens Microchemical Journal 2021;165 (2021): 106189
  2. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease, (COVID-19): A review. JAMA 2020; 324 (2019): 782–793
  3. Acquavia A, Foti L, Pascale R, Nicolo A, Brancaleone V, Cataldi TR. Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues. Talanta. 2021; 224 (2021):121862
  4. Delang L; Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153: 85–94
  5. China patent (CN104914185A). HPLC method for measuring related substances in Favipiravir. 16.09.2015
  6. Madelain JG, Nguyen THT, Jacquot F, Oestereich L, Kadota T. Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses, Antimicrob. Agents Chemother.2017; 61 (1): (2017),
  7. Smee DF, Hurst BL, Egawa H, Takahashi, K, Kadota T, Furuta Y. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virusinfected cells, J. Antimicrob. Chemother. 2009;64 (2009): 741–746
  8. Nguyen THT, Guedj J, Anglaret X, Laou´enan C, Madelain V, Taburet AM. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Negl. Trop. Dis. 2017;11 (2): e0005389
  9. Gowen BB, Sefing EJ, Westover JB, Smee, DF, Hagloch J, Furuta Y, et al., Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res. 2015;121 (2015): 132–137
  10. Safa MM, Ahmed A H, Sherin F H, Amira H. Kamal Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2021; 249 (2021): 119241 [11] Nguyen THT, Guedj J, Anglaret X, Laou´enan C, Madelain V, Taburet AM. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Negl. Trop. Dis. 2017;11 (2): e0005389
  11. A kind of Favipiravir has the HPLC assay method of related substance, Go